Posoleucel (AlloVir)(Posoleucel (AlloVir))

概要

基本信息

药物类型

T细胞疗法

别名

CMVspecific T cell therapy AlloVir、Cytomegalovirus-specific T cells (AlloVir)、Cytomegalovirusspecific T cell therapy AlloVir

+ [4]

靶点-

作用方式-

作用机制

免疫细胞毒性、T淋巴细胞替代物

治疗领域

感染泌尿生殖系统疾病其他疾病+ [1]

在研适应症-

非在研适应症

腺病毒科感染BK病毒感染巨细胞病毒感染+ [7]

原研机构

Baylor College of Medicine

在研机构-

非在研机构

AlloVir, Inc.

Baylor College of Medicine

权益机构-

最高研发阶段终止临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评孤儿药 (美国)、孤儿药 (欧盟)、优先药物（PRIME） (欧盟)、再生医学先进疗法 (美国)

登录后查看时间轴

关联

6

项与 Posoleucel (AlloVir) 相关的临床试验

NCT05179057

/ Terminated临床3期

Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial, With Cross-Over, of Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standard of Care Following Allogeneic Hematopoietic Cell Transplantation

This study will assess the safety and efficacy of Posoleucel for the treatment of adenovirus (AdV) infection in pediatric and adult allo-HCT recipients receiving standard of care (SoC).

开始日期2022-04-26

申办/合作机构

AlloVir, Inc.

NCT04605484

/ Completed临床2期

Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled, Multiple Dosing Interval, 2-period Study of the Safety, Tolerability and Effectiveness of Adoptively Transferred Posoleuccel (ALVR105) Multivirus-specific T Cells in Kidney Transplant Recipients With Either High or Low Levels of BK Viremia

The purpose of this study is to compare Posoleucel (formerly known as ALVR105; Viralym-M) to placebo in kidney transplant recipients who have high or low levels of BK virus in their blood.

开始日期2021-03-22

申办/合作机构

AlloVir, Inc.

NCT04390113

/ Terminated临床3期

Phase 3 Multicenter, Double-Blind, Placebo-Controlled Trial of Viralym-M (ALVR105) for the Treatment of Patients With Virus-Associated Hemorrhagic Cystitis After Allogeneic Hematopoietic Cell Transplant (HCT)

Study to Evaluate Viralym-M (ALVR105) for the Treatment of Virus-Associated Hemorrhagic Cystitis (HC).

开始日期2021-03-18

申办/合作机构

AlloVir, Inc.

100 项与 Posoleucel (AlloVir) 相关的临床结果

登录后查看更多信息

100 项与 Posoleucel (AlloVir) 相关的转化医学

登录后查看更多信息

100 项与 Posoleucel (AlloVir) 相关的专利（医药）

登录后查看更多信息

5

项与 Posoleucel (AlloVir) 相关的文献（医药）

2024-12-01·JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Posoleucel for BK Polyomavirus in Kidney Transplant Recipients

Article

作者: Hirsch, Hans H. ; Wilhelm, Maud ; Schaub, Stefan ; Geng, Anne

2024-08-01·Cytotherapy

Phenotypic and functional characterization of posoleucel, a multivirus-specific T cell therapy for the treatment and prevention of viral infections in immunocompromised patients

Article

作者: Leen, Ann M ; Watanabe, Ayumi ; Vasileiou, Spyridoula ; Velazquez, Yovana ; Gilmore, Sarah A ; Kuvalekar, Manik

BACKGROUND:

Deficits in T cell immunity translate into increased risk of severe viral infection in recipients of solid organ and hematopoietic cell transplants. Thus, therapeutic strategies that employ the adoptive transfer of virus-specific T cells are being clinically investigated to treat and prevent viral diseases in these highly immunocompromised patients. Posoleucel is an off-the-shelf multivirus-specific T cell investigational product for the treatment and prevention of infections due to adenovirus, BK virus, cytomegalovirus, Epstein-Barr virus, human herpesvirus 6 or JC virus.

METHODS:

Herein we perform extensive characterization of the phenotype and functional profile of posoleucel to illustrate the cellular properties that may contribute to its in vivo activity.

RESULTS AND CONCLUSIONS:

Our results demonstrate that posoleucel is enriched for central and effector memory CD4⁺ and CD8⁺ T cells with specificity for posoleucel target viruses and expressing a broad repertoire of T cell receptors. Antigen-driven upregulation of cell-surface molecules and production of cytokine and effector molecules indicative of proliferation, co-stimulation, and cytolytic potential demonstrate the specificity of posoleucel and its potential to mount a broad, polyfunctional, and effective Th1-polarized antiviral response upon viral exposure. We also show the low risk for off-target and nonspecific effects as evidenced by the enrichment of posoleucel in memory T cells, low frequency of naive T cells, and lack of demonstrated alloreactivity in vitro. The efficacy of posoleucel is being explored in four placebo-controlled clinical trials in transplant recipients to treat and prevent viral infections (NCT05179057, NCT05305040, NCT04390113, NCT04605484).

2024-05-01·Journal of the American Society of Nephrology : JASN

Posoleucel in Kidney Transplant Recipients with BK Viremia

Article

作者: Vasileiou, Spyridoula ; Nair, Vinay ; Cardarelli, Francesca ; Ma, Julie ; Young, Jo-Anne H. ; Wojciechowski, David ; Singh, Manpreet ; Lonze, Bonnie E. ; Rossi, Ana P. ; Chandraker, Anil ; Zaky, Ziad ; Sharfuddin, Asif ; Chen, Ling-Xin ; Adey, Deborah ; Dadhania, Darshana M. ; Regmi, Anil ; Gupta, Gaurav ; Ansari, Mohammed J. ; Woodle, E. Steve ; Gohh, Reginald ; Jindra, Peter T. ; Cibrik, Diane ; Jain, Divya ; Alhamad, Tarek ; Gilmore, Sarah ; Knechtle, Stuart ; Alper, Arnold ; Sharma, Akhil ; Norman, Silas ; Faravardeh, Arman ; Florescu, Diana

Key Points:

Posoleucel was generally safe, well tolerated, and associated with a greater reduction of BK viremia compared with placebo.BK viremia reduction occurred coincident with an increase in the circulating frequency of BK virus–specific T cells in posoleucel recipients.The presence and persistence of posoleucel was confirmed by T-cell receptor variable β sequencing.

Background:

Kidney transplant recipients with BK virus infection are at risk of developing BK virus–associated nephropathy, allograft rejection, and subsequent graft loss. There are no approved treatments for BK virus infection. Posoleucel is an off-the-shelf, allogeneic, multivirus-specific T-cell investigational therapy targeting BK virus, as well as five other opportunistic viruses: adenovirus, cytomegalovirus, Epstein–Barr virus, human herpesvirus 6, and John Cunningham virus.

Methods:

In this phase 2, double-blind study, kidney transplant recipients with BK viremia were randomized 1:1:1 to receive posoleucel weekly for 3 weeks and then every 14 days (bi-weekly dosing) or every 28 days (monthly dosing) or placebo for 12 weeks. Participants were followed for 12 weeks after completing treatment. The primary objective was safety; the secondary objective was plasma BK viral load reduction.

Results:

Sixty-one participants were randomized and dosed. Baseline characteristics were similar across groups. No deaths, graft-versus-host disease, or cytokine release syndrome occurred. The proportion of patients who had adverse events (AEs) judged by the investigators to be treatment-related was slightly lower in recipients of posoleucel: 20% (4 of 20 patients) and 18% (4 of 22) in those infused on a bi-weekly and monthly schedule, respectively, and 26% (5 of 19) in placebo recipients. None of the grade 3–4 AEs or serious AEs in any group were deemed treatment-related. No deaths, graft-versus-host disease, or cytokine release syndrome occurred. Three participants had allograft rejection, but none were deemed treatment-related by investigators. In posoleucel recipients, BK viremia reduction was associated with an increase in the circulating frequency of BK virus–specific T cells, and the presence and persistence of posoleucel was confirmed by T-cell receptor sequencing.

Conclusions:

Posoleucel was generally safe, well tolerated, and associated with a larger reduction of BK viremia compared with placebo. Limitations of this study include the relatively short duration of follow-up and lack of power to detect significant differences in clinical outcomes.

Clinical Trial registry name and registration number::

Study of Posoleucel (Formerly Known as ALVR105; Viralym-M) in Kidney Transplant Patients With BK Viremia, NCT04605484.

52

项与 Posoleucel (AlloVir) 相关的新闻（医药）

2025-07-25

·FierceBiotech

Memo pushes kidney drug to phase 3 despite primary endpoint miss

Memo Therapeutics will share more phase 2 data at the World Transplant Congress next month. \n A phase 2 trial of Memo Therapeutics’ kidney transplant drug candidate has missed its primary endpoint, adding to the list of setbacks in the indication. But the Swiss biotech saw promise in other aspects of the data set and outlined plans to move into phase 3.The phase 2 trial tested Memo’s anti-BK polyomavirus antibody potravitug. Investigators randomized 95 kidney transplant recipients infected with the virus to receive potravitug or placebo. At Week 20, the proportion of patients with undetectable levels of the virus in the blood was statistically no higher in the treatment arm than in the control group, causing the trial to miss its primary endpoint.However, Memo pointed to success against other measures to make the case for further development of the antibody. The treatment group had significantly higher viral response with resolution of biopsy-proven BK polyomavirus nephropathy (BKPyVAN). “This histological improvement in BKPyVAN indicated resolution of the underlying disease, decreasing from 51.2% at baseline to 31.6% at Week 20 in the treatment group, while no change was observed in the placebo group,” Memo said in a statement. Memo reported no treatment-related serious adverse events or withdrawals due to adverse events. The biotech will share more phase 2 data at the World Transplant Congress next month. In parallel, Memo is preparing to talk to regulators later this year about the design of a planned phase 3 program. Potravitug has a fast-track designation from the FDA.No drugs against the virus are approved by the FDA. Vera Therapeutics has a rival candidate, MAU868, but progress stalled after it completed phase 2 back in 2022. The company is focused on bringing another asset, atacicept, to market. AlloVir was developing posoleucel for use against BK virus, wrapping up a phase 2 trial in 2022, but phase 3 failures led the company to enter into a reverse merger last year.

临床3期快速通道临床2期临床结果

2025-01-28

·药事纵横

2024年被拒批、延迟、终止的CGT疗法

声明：因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及）;本文不构成任何投资建议。回顾 2024 年，细胞和基因疗法（CGT）领域可谓是波澜壮阔，在取得诸多突破的同时，也面临着部分疗法受挫的情况。来源：细胞基因疗法前沿据不完全统计，2024 年全球有 17 款 CGT 疗法获批上市。当然也有一部分CGT疗法遭遇挫折，或被拒批，或延迟审批或临床试验被迫终止。例如，一些企业的 CGT 产品由于在临床试验中未能达到预期的疗效终点，或者出现了安全性问题，导致审批受阻。还有部分产品因生产工艺复杂、质量控制难度大等问题，无法满足监管部门的要求，从而延迟了上市进程。具体如下：拒批 EB-101 4 月 22 日，Abeona Therapeutics 的细胞疗法prademagene zamikeracel (pz-cel，EB-101)上市申请遭拒，FDA 要求其提供治疗的有效信息及满足额外的 CMC 要求。 EB-101用于治疗隐性营养不良性大疱性表皮松解症患者。它是一款自体的细胞与基因治疗，使用逆转录病毒载体将COL7A1基因导入患者自身的皮肤细胞(角质形成细胞)，并将其移植回患者体内，以使正常的VII型胶原蛋白表达和促进伤口愈合。 Kresladi 6 月 28 日，Rocket Pharmaceuticals 的基因疗法Kresladi™ （marnegragene autotemcel; marne-cel）被拒批，FDA 要求提供有限的额外化学制造和控制 (CMC) 信息以完成审查。 Kresladi（曾用名RP-L201）用于治疗严重白细胞粘附缺陷，是一款用以治疗严重白细胞粘附缺陷-I（LAD-I）的在研基因疗法，该疗法通过慢病毒对患者的自体造血干细胞进行基因工程化改造，以递送ITGB2基因的功能性拷贝。延迟 Ryoncil：Mesoblast 的间充质干细胞疗法 Ryoncil 在审批过程中历经波折，曾收到 2 封 CRL（申请拒绝），直到 2024 年 12 月 18 日才获批上市，用于治疗激素难治性急性移植物抗宿主病。暂停或终止 vx-880 ：1 月 7 日，因两名患者死亡，Vertex 暂停细胞疗法 vx-880 的临床试验，等待独立数据监控委员会和全球监管机构对全部数据的审查。vx-880 是一种干细胞衍生的胰岛细胞疗法，用于治疗 1 型糖尿病。 Posoleucel：1月上旬，AlloVir宣布终止核心产品Posoleucel 的三项3期临床试验。Posoleucel是一种实验性的多病毒特异性T细胞疗法，AlloVir停止的3项临床试验，分别是用于预防多种病毒引起的感染或疾病，治疗病毒相关的出血性膀胱炎（vHC）和治疗腺病毒（AdV）。 fordadistrogene movaparvovec ： 5 月 7 日，一名杜氏肌营养不良患者在使用辉瑞的基因疗法 fordadistrogene movaparvovec的 2 期临床试验中去世，死因是心脏骤停。辉瑞随后暂停了其针对 4 到 8 岁男孩的随机、安慰剂对照 3 期试验 CIFFREO 中的患者交叉试验。两个月后，辉瑞宣布 3 期 CIFFREO 研究未达到主要终点，也未达到关键次要终点，决定终止开发这款产品。 giroctocogene fitelparvovec： 12 月 30 日，辉瑞宣布终止与 Sangamo 在 A 型血友病基因疗法 giroctocogenefitelparvovec上的合作。辉瑞经多方统筹分析，认为目前患者对额外基因治疗选择的兴趣非常有限。 spk-3006 ：是由罗氏子公司 Spark Therapeutics 开发的一种肝靶向的 AAV 试验性基因疗法，用于治疗庞贝病。在罗氏 2024 年上半年的管线梳理中，决定剔除该项目，停止了对其的临床开发。停止试验的决定不是由于安全问题，而是作为 Spark 内部战略组合优先级的一部分做出的。 GLPG5301：Galapagos 公司研发的一款 BCMA CAR-T 疗法 GLPG5301，主要用于治疗成人复发 / 难治性多发性骨髓瘤。因一名患者出现帕金森综合症而在 2024 年 8 月暂停所有临床。不过好在经过审查和采取额外的安全措施后，已于 2024 年第三季度恢复招募。退出 Alofisel（Darvadstrocel）：是一种同种异体间充质干细胞疗法，于2018年在欧盟获批，用于治疗对至少一种常规或生物疗法无效的非活动性/轻度活动性管腔克罗恩病的成人患者的复杂肛周瘘‌。然而，12月13日，武田制药公司宣布自愿撤销Alofisel在欧盟的营销授权。这一决定是基于补充临床试验结果，显示该药物未能达成主要和次要终点，且疗效不如预期‌。回顾 2024 年 FDA 对这些 CGT 疗法的审批动态，无论是获批上市、拒绝还是延迟，都深刻影响着患者的治疗希望、企业的发展命运以及整个行业的未来走向。审批过程中的种种要求与决策，不仅是对疗法安全性和有效性的严格把关，更是推动 CGT 领域朝着更加规范、成熟方向发展的重要力量。参考资料：公开资料

基因疗法细胞疗法上市批准ASH会议临床2期

2024-11-08

·Firstwordpharma

AlloVir seeks redemption via merger with retinal disease biotech

Looking to bounce back following clinical setbacks with its lead asset and a gutting of its workforce, cell therapy developer AlloVir announced that it is merging with Kalaris Therapeutics in an all-stock transaction. The key draw for AlloVir is Kalaris' retinal disease asset TH103, an anti-VEGF therapy currently in Phase I for patients with neovascular age-related macular degeneration (AMD).The planned merger comes less than a year after AlloVir was forced to discontinue late-stage trials of its lead asset posoleucel, a multi-virus-specific T-cell therapy that was being developed for off-the-shelf use to treat viral infections in transplant patients. The failures prompted AlloVir in January to slash its workforce by 95% in order to conserve cash."AlloVir ran a thorough and strategic process, and we believe that this transaction represents the company's commitment to delivering value to the AlloVir stockholders," said CEO Diana Brainard. TH103, she added, has "the potential to disrupt the large anti-VEGF market, with near-term, value-inflecting milestones and a well-credentialed management team to lead the combined company."Less frequent dosingDeveloped by VEGF pioneer, Napoleone Ferrara, TH103 is a fully humanised, recombinant fusion protein engineered to inhibit VEGF, the key driver of pathological angiogenesis and exudation in retinal diseases. Data from head-to-head preclinical studies indicated it has longer-acting and increased anti-VEGF activity compared to Bayer and Regeneron's Eylea (aflibercept)."This fusion protein was specifically engineered to utilise the natural configuration of important domains of VEGF receptor 1 and has demonstrated both potent anti-VEGF activity and sustained ocular residence time in preclinical studies. This could potentially lead to enhanced durability with less frequent dosing in the clinical setting," Ferrara said.Some major players already market longer-acting treatments. Roche's Vabysmo (faricimab-svoa), which blocks two causes of wet AMD, was approved in 2022 and allows patients to space out injections up to every four months, rather than every two months with the original version Eylea. A higher-dose formulation, known as Eylea HD, has since hit the market in the US and Europe, and also allows patients to go up to four months between treatments. See – KOL Views Q&A: Leading expert pegs odds-on favourite among long-acting TKIs – but Eylea, Vabysmo not key rival.Initial data from the Phase I trial of TH103 in treatment-naïve patients with neovascular AMD are due in the third quarter of 2025. The drug will also be explored in other diseases such as diabetic macular oedema and retinal vein occlusion.Under the terms of the merger deal, AlloVir will acquire 100% of Kalaris' equity in an all-stock transaction. Upon completion, AlloVir and Kalaris stockholders are expected to own approximately 25% and 75% of the combined company, respectively. The merged entity, which will run under the Kalaris Therapeutics name, is expected to have about $100 million in cash to fund operations into the fourth quarter of 2026. The transaction is expected to close early next year.

临床1期细胞疗法上市批准并购免疫疗法

100 项与 Posoleucel (AlloVir) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
腺病毒科感染	临床3期	澳大利亚	AlloVir, Inc.	2022-03-24
腺病毒科感染	临床3期	法国	AlloVir, Inc.	2022-03-24
BK病毒感染	临床3期	美国	AlloVir, Inc.	2021-03-18
BK病毒感染	临床3期	法国	AlloVir, Inc.	2021-03-18
BK病毒感染	临床3期	意大利	AlloVir, Inc.	2021-03-18
BK病毒感染	临床3期	韩国	AlloVir, Inc.	2021-03-18
BK病毒感染	临床3期	西班牙	AlloVir, Inc.	2021-03-18
BK病毒感染	临床3期	瑞典	AlloVir, Inc.	2021-03-18
BK病毒感染	临床3期	英国	AlloVir, Inc.	2021-03-18
出血性膀胱炎	临床3期	美国	AlloVir, Inc.	2021-03-18

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04605484 (CTgov)	临床2期	BK病毒感染 \| 病毒血症	61	Placebo (visually identical to Posoleucel)	觸鬱淵蓋醖鹽願鹹憲構 = 壓觸膚簾憲糧齋鑰繭積壓選願鹹壓廠艱簾簾淵 (鬱網餘醖鏇鹹廠顧製鏇, 鏇廠餘鹹築糧齋顧鏇遞 ~ 憲醖鬱遞築廠選糧範膚) 更多	-	2024-05-16
NCT05305040 (Phase 2 Trial of Posoleucel \| Prevent, CTgov)	临床2/3期	JC病毒感染 \| BK病毒感染 \| 腺病毒科感染 ... 更多	451	Posoleucel (ALVR105) (Posoleucel (ALVR105))	醖齋遞鑰選鬱淵齋鹹獵(蓋簾夢繭觸獵鑰壓廠襯) = 築繭鹹餘簾範衊壓餘夢壓窪製艱衊襯蓋構壓蓋 (鑰鹹糧鹹齋壓網鏇淵觸, 0.44) 更多	-	2024-05-16
NCT05305040 (Phase 2 Trial of Posoleucel \| Prevent, CTgov)	临床2/3期	JC病毒感染 \| BK病毒感染 \| 腺病毒科感染 ... 更多	451	Placebo (Placebo)	醖齋遞鑰選鬱淵齋鹹獵(蓋簾夢繭觸獵鑰壓廠襯) = 廠糧壓糧願鏇簾衊餘膚壓窪製艱衊襯蓋構壓蓋 (鑰鹹糧鹹齋壓網鏇淵觸, 0.42) 更多	-	2024-05-16
NCT04390113 (CTgov)	临床3期	BK病毒感染 \| 出血性膀胱炎	97	Posoleucel (ALVR105) (Posoleucel (ALVR105))	糧網願鏇淵夢網願蓋醖(觸衊壓鏇鏇觸餘淵醖鬱) = 範網構餘蓋願鹽鏇簾鑰鹹襯齋窪繭鹹選壓蓋獵 (鹽簾憲醖憲餘窪壓餘夢, 鹹廠鹽簾獵製築糧餘獵 ~ 壓艱鏇鹹選鏇夢獵廠網) 更多	-	2024-05-14
NCT04390113 (CTgov)	临床3期	BK病毒感染 \| 出血性膀胱炎	97	Placebo (Placebo)	糧網願鏇淵夢網願蓋醖(觸衊壓鏇鏇觸餘淵醖鬱) = 膚獵遞鬱廠積簾網夢簾鹹襯齋窪繭鹹選壓蓋獵 (鹽簾憲醖憲餘窪壓餘夢, 鑰廠鑰繭觸淵憲憲窪襯 ~ 範鏇積簾積鬱衊餘繭構) 更多	-	2024-05-14
NCT05179057 (CTgov)	临床3期	腺病毒科感染	57	Placebo+Posoleucel (Posoleucel, Then Placebo)	積遞醖願蓋遞鹹淵糧鑰 = 壓選築齋襯夢繭繭鹹餘積顧夢餘廠觸築築鬱觸 (築簾鹹築襯範繭簾齋鹽, 憲願糧範積齋襯製製鹽 ~ 鹽簾窪網餘範遞鏇衊鹽)	-	2024-05-08
NCT05179057 (CTgov)	临床3期	腺病毒科感染	57	Placebo+Posoleucel (Placebo, Then Posoleucel)	積遞醖願蓋遞鹹淵糧鑰 = 醖構構醖鑰獵鹽憲範糧積顧夢餘廠觸築築鬱觸 (築簾鹹築襯範繭簾齋鹽, 蓋鑰襯遞顧鏇膚鑰範範 ~ 齋夢鏇觸選艱衊鬱鏇範)	-	2024-05-08
NCT04693637 (P325 \| O095 \| Prevent, CTgov)	临床2/3期	JC病毒感染 \| BK病毒感染 \| 腺病毒科感染 ... 更多	26	Posoleucel (ALVR105)	夢願鹹繭構餘醖糧鬱願 = 鏇壓鹽獵衊醖蓋齋齋糧鏇積鹹獵窪壓窪蓋衊製 (網夢壓鏇糧簾簾夢夢齋, 廠網衊襯顧網艱簾願夢 ~ 糧淵獵夢艱鑰廠壓醖選) 更多	-	2024-05-07
NCT04605484 \| NCT04390113 \| NCT05305040 \| NCT05179057 (Tandem Meetings ASTCT and CIBMTR2024)	临床3期	病毒感染	-	Posoleucel (PSL)	築鏇積鏇蓋鹹鏇糧顧範(艱醖簾壓膚鹽築鹹鑰膚) = 觸積糧夢鏇鹹願鑰構築夢繭觸網選願範艱醖鹹 (齋範鹽膚蓋蓋憲廠夢艱, <3) 更多	积极	2024-02-01
NCT04693637 \| NCT05305040 (EBMT2023) 人工标引	临床2/3期	JC病毒感染 \| BK病毒感染 \| 腺病毒科感染 ... 更多	26	posoleucel	膚壓製淵齋遞壓製淵醖(顧餘衊遞選蓋遞襯艱淵) = 遞範窪蓋壓糧築構鏇選築鏇鏇糧範顧襯遞鬱獵 (糧餘鬱膚顧鑰鑰醖簾艱 ) 更多	积极	2023-04-26
NCT04693637 (O095, EBMT2023)	临床2期	病毒感染	-	Posoleucel	鏇衊鏇觸製淵膚鏇積積(築選鹹憲夢顧窪製觸醖) = 5 patients (19%) had acute GVHD Grade II-IV 鹹壓夢鑰積廠醖鑰憲鹽 (鏇獵衊遞艱鑰鏇鹽糧蓋 ) 更多	-	2023-04-23
NCT05305040 (Phase 2 Trial of Posoleucel, Tandem Meetings ASTCT and CIBMTR2023)	临床2期	病毒感染	26	Posoleucel (PSL)	廠艱淵顧艱願醖憲膚遞(夢製鹽鏇糧憲積餘願廠) = 鬱窪簾壓築齋鏇衊憲餘構觸獵觸鬱齋齋製選淵 (範齋範構鹹襯蓋蓋淵鬱 ) 更多	积极	2023-02-01
NCT05305040 (ASH 12022 \| ASH 22022) 人工标引	临床2期	病毒感染	26	Posoleucel	鏇鏇艱糧淵夢廠願壓餘(糧醖淵範構顧製簾繭壓) = 簾壓襯願築鏇鬱願鑰窪繭夢網餘顧蓋憲壓網淵 (窪憲糧醖鹹襯齋鬱壓選 ) 更多	积极	2022-11-15